AEterna Zentaris (AEZS) Stock: Here’s Why It’s Climbing & What To Watch!

AEterna Zentaris Inc. (NASDAQ: AEZS)

AEterna Zentaris is having an incredibly strong day in the market today. Early on, it looked like it was going to be a relatively normal session. The stock was in the green, but the gains weren’t anything to write home about. However, that changed quickly when the stock started spiking upward minutes ago. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching with regard to AEZS ahead.





What We’re Seeing From AEZS

As mentioned above, AEterna Zentaris looked like it was going to be off to a relatively normal day early on. Shortly after the closing bell, the stock was in the green, but not by much. From there, we saw slow, yet steady gains. That is, until minutes ago when the stock started making a run for the top. At the moment (11:34), the stock is trading at $3.69 per share after a gain of $0.19 per share (5.40%) thus far today.

Why The Stock Is Gaining

As usual, when we were notified by Trade Ideas┬áthat AEZS was headed upward, the CNA Finance team started to do some digging to see what was causing the movement. In this case, it didn’t take us long to dig up the dirt. At the end of the day, we’re seeing a ton of social excitement, and for good reason.




No matter what social network you use, if you search for AEterna Zentaris, chances are that you’re going to see the same thing. Investors are incredibly excited because the company is on the verge of releasing data from two Phase 3 clinical studies. In the first study, AEZS is evaluating Macrilen(TM) as a treatment for Growth Hormone Deficiency. In the second, the company is evaluating Zoptrex(R) as a treatment for Endometrial cancer. Ultimately, as we get closer and closer to the data, investors are likely to get more and more excited.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AEZS. In particular, we’re interested to see just how well the 2 Phase 3 studies went. Nonetheless, we’ll keep close tabs on the news and bring you the information when it becomes available.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of PublicDomainPictures.net]

Leave a Comment